# Patient Peptide Protocol Template

**For Healthcare Practitioners**

---

## Patient Information

**Patient Name:** ___________________________  
**Date of Birth:** ___________________________  
**Medical Record #:** ___________________________  
**Protocol Start Date:** ___________________________  
**Prescribing Practitioner:** ___________________________

---

## Primary Indication

**Condition/Goal:** ___________________________

**ICD-10 Code(s):** ___________________________

**Previous Treatments Tried:** ___________________________

---

## Peptide Protocol

### Peptide #1: ___________________________

**Indication:** ___________________________

**Dosing:**
- Dose: ___________ mcg/mg
- Route: ☐ Subcutaneous ☐ Intramuscular ☐ Intranasal ☐ Oral
- Frequency: ☐ Daily ☐ 2x/day ☐ 3x/week ☐ 2x/week ☐ Other: ___________
- Timing: ☐ Morning ☐ Evening ☐ Before bed ☐ Post-workout ☐ Other: ___________

**Reconstitution (if applicable):**
- Vial size: ___________ mg
- Bacteriostatic water: ___________ mL
- Final concentration: ___________ mg/mL

**Administration Instructions:**
- Injection site: ☐ Abdomen ☐ Thigh ☐ Deltoid ☐ Other: ___________
- Syringe type: ☐ Insulin (U-100) ☐ Standard mL
- Volume per dose: ___________ mL or ___________ units

**Duration:** ___________ weeks/months

**Expected Timeline for Results:** ___________________________

---

### Peptide #2 (if applicable): ___________________________

**Indication:** ___________________________

**Dosing:**
- Dose: ___________ mcg/mg
- Route: ☐ Subcutaneous ☐ Intramuscular ☐ Intranasal ☐ Oral
- Frequency: ☐ Daily ☐ 2x/day ☐ 3x/week ☐ 2x/week ☐ Other: ___________
- Timing: ☐ Morning ☐ Evening ☐ Before bed ☐ Post-workout ☐ Other: ___________

**Reconstitution (if applicable):**
- Vial size: ___________ mg
- Bacteriostatic water: ___________ mL
- Final concentration: ___________ mg/mL

**Administration Instructions:**
- Injection site: ☐ Abdomen ☐ Thigh ☐ Deltoid ☐ Other: ___________
- Syringe type: ☐ Insulin (U-100) ☐ Standard mL
- Volume per dose: ___________ mL or ___________ units

**Duration:** ___________ weeks/months

**Expected Timeline for Results:** ___________________________

---

### Peptide #3 (if applicable): ___________________________

**Indication:** ___________________________

**Dosing:**
- Dose: ___________ mcg/mg
- Route: ☐ Subcutaneous ☐ Intramuscular ☐ Intranasal ☐ Oral
- Frequency: ☐ Daily ☐ 2x/day ☐ 3x/week ☐ 2x/week ☐ Other: ___________
- Timing: ☐ Morning ☐ Evening ☐ Before bed ☐ Post-workout ☐ Other: ___________

**Reconstitution (if applicable):**
- Vial size: ___________ mg
- Bacteriostatic water: ___________ mL
- Final concentration: ___________ mg/mL

**Administration Instructions:**
- Injection site: ☐ Abdomen ☐ Thigh ☐ Deltoid ☐ Other: ___________
- Syringe type: ☐ Insulin (U-100) ☐ Standard mL
- Volume per dose: ___________ mL or ___________ units

**Duration:** ___________ weeks/months

**Expected Timeline for Results:** ___________________________

---

## Baseline Assessment

**Date:** ___________________________

### Vital Signs
- Blood Pressure: ___________ / ___________ mmHg
- Heart Rate: ___________ bpm
- Weight: ___________ lbs/kg
- BMI: ___________

### Baseline Labs (check all completed)
☐ Comprehensive Metabolic Panel  
☐ Complete Blood Count  
☐ Lipid Panel  
☐ HbA1c  
☐ Thyroid Panel (TSH, Free T3/T4)  
☐ IGF-1 (for GH therapy)  
☐ CRP (for inflammatory conditions)  
☐ Other: ___________________________

### Baseline Assessments (check all completed)
☐ Pain Scale (VAS 0-10): ___________  
☐ Cognitive Testing (MoCA/MMSE): ___________  
☐ Mood/Anxiety Scales (GAD-7/PHQ-9): ___________  
☐ Body Composition (DEXA): ___________  
☐ Range of Motion: ___________  
☐ Functional Testing: ___________  
☐ Imaging: ___________________________  
☐ Other: ___________________________

---

## Monitoring Schedule

### Week 2
- ☐ Symptom review (phone/telehealth)
- ☐ Adverse event assessment
- ☐ Injection technique review
- ☐ Patient-reported outcomes

### Week 4
- ☐ Office visit
- ☐ Vital signs
- ☐ Symptom review
- ☐ Labs (specify): ___________________________
- ☐ Patient-reported outcomes

### Week 8
- ☐ Office visit
- ☐ Vital signs
- ☐ Symptom review
- ☐ Labs (specify): ___________________________
- ☐ Assessments (specify): ___________________________

### Week 12
- ☐ Office visit
- ☐ Vital signs
- ☐ Comprehensive labs (CMP, CBC, lipids, HbA1c)
- ☐ Peptide-specific labs: ___________________________
- ☐ Repeat baseline assessments
- ☐ Protocol adjustment if needed

### Week 24
- ☐ Office visit
- ☐ Vital signs
- ☐ Comprehensive labs
- ☐ Repeat baseline assessments
- ☐ Protocol continuation or discontinuation decision

---

## Safety Monitoring

### Contraindications (check if applicable)
☐ Active cancer or history of cancer (within 5 years)  
☐ Pregnancy or breastfeeding  
☐ Severe kidney disease (eGFR <30)  
☐ Severe liver disease (cirrhosis)  
☐ Uncontrolled diabetes (HbA1c >9%)  
☐ Uncontrolled hypertension (>160/100)  
☐ History of pancreatitis (for GLP-1 agonists)  
☐ MEN2 or medullary thyroid cancer (for GLP-1 agonists)  
☐ Active autoimmune disease (for immune stimulators)  
☐ Other: ___________________________

### Drug Interactions (check if applicable)
☐ Insulin or sulfonylureas (hypoglycemia risk with GLP-1)  
☐ Immunosuppressants (avoid with immune stimulators)  
☐ Antihypertensives (monitor with Semax)  
☐ Other: ___________________________

### Adverse Event Checklist (review at each visit)
☐ Injection site reactions  
☐ Nausea/vomiting  
☐ Diarrhea/constipation  
☐ Joint pain  
☐ Fluid retention/edema  
☐ Headache  
☐ Dizziness  
☐ Palpitations  
☐ Mood changes  
☐ Sleep disturbances  
☐ Other: ___________________________

**Action if adverse events:** ___________________________

---

## Patient Education & Informed Consent

### Topics Discussed (check all)
☐ Off-label use and limited evidence for many peptides  
☐ Proper injection technique and site rotation  
☐ Storage requirements (refrigeration)  
☐ Expected timeline for results  
☐ Potential adverse effects  
☐ Monitoring requirements and costs  
☐ Drug interactions  
☐ When to contact practitioner (red flags)  
☐ Alternative therapies available  
☐ Right to discontinue at any time

**Patient Signature:** ___________________________  
**Date:** ___________________________

**Practitioner Signature:** ___________________________  
**Date:** ___________________________

---

## Red Flags - When to Contact Practitioner Immediately

- Severe abdominal pain (pancreatitis concern)
- Chest pain or shortness of breath
- Severe allergic reaction (hives, difficulty breathing)
- Persistent vomiting or inability to keep fluids down
- Signs of infection at injection site (redness, warmth, pus)
- Severe or worsening symptoms
- Any other concerning symptoms

**Emergency Contact:** ___________________________  
**Office Phone:** ___________________________  
**After-Hours Contact:** ___________________________

---

## Protocol Adjustments

### Date: ___________________________
**Adjustment:** ___________________________  
**Rationale:** ___________________________  
**Practitioner Initials:** ___________

### Date: ___________________________
**Adjustment:** ___________________________  
**Rationale:** ___________________________  
**Practitioner Initials:** ___________

### Date: ___________________________
**Adjustment:** ___________________________  
**Rationale:** ___________________________  
**Practitioner Initials:** ___________

---

## Protocol Outcome Assessment (at completion)

**Date:** ___________________________

**Primary Goal Achievement:**
☐ Fully achieved  
☐ Partially achieved  
☐ Not achieved

**Objective Improvements:**
- ___________________________
- ___________________________
- ___________________________

**Subjective Improvements:**
- ___________________________
- ___________________________
- ___________________________

**Adverse Events Experienced:**
- ___________________________
- ___________________________

**Overall Patient Satisfaction:** ☐ Very satisfied ☐ Satisfied ☐ Neutral ☐ Dissatisfied

**Plan:**
☐ Continue current protocol  
☐ Adjust protocol (specify): ___________________________  
☐ Discontinue peptide therapy  
☐ Transition to maintenance protocol  
☐ Other: ___________________________

**Practitioner Notes:** ___________________________

**Practitioner Signature:** ___________________________  
**Date:** ___________________________

---

**Template Version:** 1.0  
**Last Updated:** November 29, 2025  
**Source:** DrsPeptides.com

**For Healthcare Practitioner Use Only**
